13F HOLDINGS REPORT
Foresite Capital Management VI LLC
Quarter ended Q3 2025 · Filed November 14, 2025 · Accession 0001104659-25-112509
Total Value
$258.9M
Positions
12
Other Managers
0
Confidential Omitted
No
Holdings (12)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG Oncology, Inc. | CGON | 2,221,474 | $89.5M | 34.57% |
| 2 | RAPT Therapeutics, Inc. | 75382E208 | 1,562,500 | $40.3M | 15.57% |
| 3 | Centessa Pharmaceuticals plc | CNTA | 1,314,019 | $31.9M | 12.31% |
| 4 | Verastem, Inc. | VSTM | 2,615,120 | $23.1M | 8.92% |
| 5 | ALUMIS INC. | ALMS | 4,247,670 | $16.9M | 6.55% |
| 6 | Denali Therapeutics Inc. | DNLI | 1,000,000 | $14.5M | 5.61% |
| 7 | Corvus Pharmaceuticals, Inc. | CRVS | 1,731,233 | $12.8M | 4.93% |
| 8 | Akero Therapeutics, Inc. | 00973Y108 | 244,900 | $11.6M | 4.49% |
| 9 | Kymera Therapeutics, Inc. | KYMR | 146,332 | $8.3M | 3.20% |
| 10 | Hinge Health, Inc. | HNGE | 135,000 | $6.6M | 2.56% |
| 11 | Avidity Biosciences, Inc. | 05370A108 | 40,000 | $1.7M | 0.67% |
| 12 | CASI Pharmaceuticals, Inc. | CASIF | 979,956 | $1.6M | 0.63% |